Koronavirüs aşılamasının başlangıcından itibaren yoğun bakımda yatan, entübe olan ve vefat eden koronavirüs hastalarının aşılanma durumunun değerlendirilmesi
Küçük Resim Yok
Tarih
2025
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu çalışmanın amacı COVID-19 hastalarında Koronavirüs aşısının yoğun bakımda yatan, entübe olan ve vefat eden Koronavirüs hastalarına etkisini araştırmaktır.Koronavirüse karşı aşılanmanın başlangıç tarihi olan 13.01.2021 tarihinden 13.01.2022 tarihine kadar geçen 1 yıllık süre içinde, bu hastanelerin COVID-19 yoğun bakım servislerinde tedavi gören 1.545 Koronavirüs hastası; yaş, cinsiyet, testlerinin pozitif çıktığının kaçıncı gününde yoğun bakıma yattıkları, kaçıncı gününde entübe oldukları ve kaçıncı gününde vefat ettikleri, yaptırılan Koronavirüs aşılarının dozları ve türleri açısından incelenmiştir. Hasta verilerine ulaşılırken Sağlık Bakanlığı'nın Halk Sağlığı Yönetim Sistemi (HSYS), AŞILA programı, E-Nabız verileri ile hastanelerin Hastane Bilgi Yönetim Sistemi otomasyon programlarından faydalanılmıştır. Tanımlayıcı istatistikler sayı ve yüzde olarak verilmiş; normal dağılıma uymayan veriler ortanca, minimum-maksimum verileri ile sunulmuştur. İstatistik anlamlılığı değerlendirmek için Mann-Withney U testi kullanılmıştır. Çalışmaya yoğun bakımda yatan ve verilerine ulaşılabilen 1.480 kişi alınmıştır. Katılımcıların yaş ortancası 69.0 (0.0-102.0) ve %54.0'i erkektir. Hastaların %45.2'si entübe edilmiş olup pozitiflik tarihinden itibaren entübasyon tarihi arasında geçen süre ortancası 8.0 (0.0-85.0) gündür. Hastaların %60.6'sı vefat etmiş olup pozitiflik tarihinden itibaren vefat tarihi arasında geçen süre ortancası 14.0 (0.0-99.0) gündür. Kadın katılımcıların yaş ortancası 72.0 (0.0-102.0) olup erkek katılımcıların yaş ortancasına göre daha yüksektir (p<0.001). Aşı verisine ulaşılabilen katılımcı sayısı 1.476'dır. Bu katılımcıların %35.6'sı hiç Koronavirüs aşısı yaptırmamıştır. %52.2'si 1.doz olarak Sinovac aşısı %12.2'si Biontech aşısı yaptırmıştır. Katılımcıların %45.6'sı 2. Doz olarak Sinovac, %10.3'ü Biontech yaptırmıştır. Katılımcıların %12.6'sı 3. Doz olarak Sinovac, %10.6'sı Biontech yaptırmıştır. Hastalarda entübe olma oranı 1. dozda Sinovac yaptıranlarda Biontech yaptıranlara ve aşısız olanlara göre, aşısız olanlarda Biontech yaptıranlara göre daha yüksektir (p<0,001). Hastalarda entübe olma oranı 2. dozda Sinovac ve Biontech yaptıranlarda hiç aşı yaptırmamış olanlara göre; Biontech yaptıranlarda Sinovac yaptıranlara göre daha düşüktür (p<0,001). Hastalarda entübe olma oranı 3. Ve 4. dozda Sinovac ve Biontech yaptıranlarda hiç aşı yaptırmamış olanlara göre daha düşüktür (p<0,001). 5. dozda Biontech yaptıranlarda entübasyon sıklığı aşısız olanlara göre daha düşüktür (p<0,001).Bu çalışmanın sonuçlarında aşı yapılmasının yoğun bakım yatış, entübasyon ve vefat etme durumlarına karşı koruyucu etkisi gösterilmiştir. Ayrıca kronik hastalıkların, ileri yaşın ve erkek cinsiyetin COVID-19 hastalığının prognozunu kötü yönde etkilediği de sonuçlar arasındaydı.
The aim of this study is to investigate the effect of the Coronavirus vaccine on COVID-19 patients who are hospitalized in intensive care, intubated, and deceased.In the 1-year period from the start date of vaccination against Coronavirus, 13.01.2021, to 13.01.2022, 1,545 Coronavirus patients treated in the Coronavirus intensive care units of these hospitals were examined in terms of age, gender, the day their tests were positive and on which day they were admitted to the intensive care unit, the day they were intubated and the day they died, and the doses and types of Coronavirus vaccines administered. While accessing patient data, the Ministry of Health's Public Health Management System (HSYS), AŞILA program, E-Pulse data, and the hospitals' Hospital Information Management System automation programs were used. Descriptive statistics are given as numbers and percentages; data that do not conform to normal distribution are presented with median, minimum-maximum data. The Mann-Withney U test was used to evaluate statistical significance.The study included 1,480 individuals hospitalized in intensive care and whose data were accessible. The median age of the participants was 69.0 (0.0-102.0) and 54.0% were male. 54.8% of the patients were intubated, and the median time from the date of positivity to the date of intubation was 8.0 (0.0-86.0) days. 60.6% of the patients died, and the median time from the date of positivity to the date of death was 14.0 (0.0-99.0) days. The median age of the female participants was 72.0 (0.0-102.0), which is higher than the median age of the male participants (p<0.001). The number of participants with accessible vaccination data was 1,476. 35.6% of these participants had never received a Coronavirus vaccine. 52.2% had Sinovac vaccine as the 1st dose and 12.2% had Biontech vaccine. 45.6% of the participants had Sinovac as the 2nd dose and 10.3% had Biontech. 12.6% of the participants had Sinovac as the 3rd dose and 10.6% had Biontech. The rate of intubation in patients was higher in those who had Sinovac as the 1st dose compared to those who had Biontech and those who were unvaccinated and higher in those who were unvaccinated compared to those who had Biontech (p<0.001). The rate of intubation in patients was lower in those who had Sinovac and Biontech as the 2nd dose compared to those who had no vaccination and lower in those who had Biontech than those who had Sinovac (p<0.001). The rate of intubation in patients who received the 3rd and 4th doses of Sinovac and Biontech was lower than those who had never been vaccinated (p<0.001). The frequency of intubation in patients who received the 5th dose of Biontech was lower than those who were not vaccinated (p<0.001).The results of this study showed that vaccination has a protective effect against intensive care admission, intubation, and death. In addition, chronic diseases, advanced age, and male gender had a negative effect on the prognosis of COVID-19 disease.
The aim of this study is to investigate the effect of the Coronavirus vaccine on COVID-19 patients who are hospitalized in intensive care, intubated, and deceased.In the 1-year period from the start date of vaccination against Coronavirus, 13.01.2021, to 13.01.2022, 1,545 Coronavirus patients treated in the Coronavirus intensive care units of these hospitals were examined in terms of age, gender, the day their tests were positive and on which day they were admitted to the intensive care unit, the day they were intubated and the day they died, and the doses and types of Coronavirus vaccines administered. While accessing patient data, the Ministry of Health's Public Health Management System (HSYS), AŞILA program, E-Pulse data, and the hospitals' Hospital Information Management System automation programs were used. Descriptive statistics are given as numbers and percentages; data that do not conform to normal distribution are presented with median, minimum-maximum data. The Mann-Withney U test was used to evaluate statistical significance.The study included 1,480 individuals hospitalized in intensive care and whose data were accessible. The median age of the participants was 69.0 (0.0-102.0) and 54.0% were male. 54.8% of the patients were intubated, and the median time from the date of positivity to the date of intubation was 8.0 (0.0-86.0) days. 60.6% of the patients died, and the median time from the date of positivity to the date of death was 14.0 (0.0-99.0) days. The median age of the female participants was 72.0 (0.0-102.0), which is higher than the median age of the male participants (p<0.001). The number of participants with accessible vaccination data was 1,476. 35.6% of these participants had never received a Coronavirus vaccine. 52.2% had Sinovac vaccine as the 1st dose and 12.2% had Biontech vaccine. 45.6% of the participants had Sinovac as the 2nd dose and 10.3% had Biontech. 12.6% of the participants had Sinovac as the 3rd dose and 10.6% had Biontech. The rate of intubation in patients was higher in those who had Sinovac as the 1st dose compared to those who had Biontech and those who were unvaccinated and higher in those who were unvaccinated compared to those who had Biontech (p<0.001). The rate of intubation in patients was lower in those who had Sinovac and Biontech as the 2nd dose compared to those who had no vaccination and lower in those who had Biontech than those who had Sinovac (p<0.001). The rate of intubation in patients who received the 3rd and 4th doses of Sinovac and Biontech was lower than those who had never been vaccinated (p<0.001). The frequency of intubation in patients who received the 5th dose of Biontech was lower than those who were not vaccinated (p<0.001).The results of this study showed that vaccination has a protective effect against intensive care admission, intubation, and death. In addition, chronic diseases, advanced age, and male gender had a negative effect on the prognosis of COVID-19 disease.
Açıklama
Anahtar Kelimeler
Halk Sağlığı, Public Health
